Investor Relations

Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer

Read Press Release

2023 Annual Meeting of Shareholders

View All Events

Latest Financial Results

Q1 2024

Quarterly Results

Ended Mar 31, 2024

Stock Information

Symbol NYSE American: OGEN
Price Loading...
Change Loading...
Day Range Loading...
52 Wk Range Loading...

Company Overview

Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases including coronaviruses and multidrug-resistant organisms. Its lead product is Terra CoV-2, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. The Terra CoV-2 program leverages coronavirus spike protein research licensed from the NIH and the NRC with a focus on reducing viral transmission and offering a more patient-friendly intranasal administration. Its lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics. In October of 2023, Oragenics announced the signing of a definitive agreement with Odyssey Health, Inc. to acquire assets related to their proprietary neurological drug therapies, including their proprietary formulation and nasal delivery system. The assets include drug candidates for treating mild traumatic brain injury, also known as concussion, and for treating Niemann Pick Disease Type C.

Contact Information

Investor Relations
LHA Investor Relations
Tirth T. Patel
Vice President
T: 212.201.6614
tpatel@lhai.com

Transfer Agent
Continental Stock Transfer and Trust Company
17 Battery Place
New York, NY 10004
T: 212-509-4000